Results of surgical and somatostatin analog therapies and their combination in acromegaly: A retrospective analysis of the German Acromegaly Register

European Journal of Endocrinology

Volumn 159, Issue 5, 2008, Pages 525-532

  Petersenn, Stephan ^a   Buchfelder, M ^b   Reincke, M ^c   Strasburger, C M ^d   Franz, H ^e   Lohmann, R ^e   Quabbe, H J ^d   Plockinger U ^d   Allolio, B ^g   Badenhoop, K ^g   Bender, G ^g   Biering, H ^g   Blossey, H C ^g   Blum, H ^g   Bogner, U ^g   Brabant, G ^g   Caspar Bell, G ^g   Demtroder F ^g   Diederich, S ^g   Droste, M ^g   Engelbach, M ^g   Faust, M ^g   Finke, R ^g   Folsch U R ^g   Gain, T ^g   Graf K J ^g   Gerbert, B ^g   Grussendorf M ^g   Hampel, R ^g   Happ, J ^g   Hackmann, C ^g   Hehrmann, R ^g   Heike, M ^g   Herrmann, B L ^g   Hoffken K ^g   Hufner M ^g   Jacobeit, J ^g   Jaursch Hancke, C ^g   Jockenhovel F ^g   Knippert, A ^g   Koch, C ^g   Kornely, E ^g   Krone, W ^g   Lehnert, H ^g   Levasseur, S ^g   Lossner C ^g   Mann, K ^g   Matern, S ^g   Meuser, J ^g   Meyer, A ^g   Minnemann, T ^g   Monig H I ^g   Muller O A ^g   Paschke, R ^f   Pfeiffer, A ^g   Raue, F ^g   Reschke, K ^g   Rudorff, K H ^g   Ruhle H ^g   Santen, R ^g   Schofl C ^g   Schopohl, J ^g   Schories, M ^g   Schroder F ^g   Strasburger, C J ^g   Sturmvoll, M ^g   Tharandt, L ^g   Tuschy, U ^g   von Werder, K ^g   Weber, M M ^g   Wiedenmann, B ^g   Wiesner, T D ^g   Wurl K ^g   Zeuzem, S ^g   more..

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Lohmann and Birkner Health Care Consulting GmbH   (Germany)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g University of Leipzig ^*

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DATA COLLECTION METHOD; GERMANY; HUMAN; HYPOPHYSIS FUNCTION; HYPOPITUITARISM; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MICROADENOMA; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; TREATMENT INDICATION;

ACROMEGALY; ADENOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY GLAND; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 56749158222     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0498     Document Type: Article

References (44)

1. Erturk E, Tuncel E, Kiyici S, Ersoy C, Duran C & Imamoglu S. Outcome of surgery for acromegaly performed by different surgeons: importance of surgical experience. Pituitary 2005 8 93-97.
2. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S & Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2005 90 4465-4473.
3. van der Lely AJ, de Herder WW & Lamberts SW. New medical treatment for acromegaly. Pituitary 1999 2 89-92.
4. van der Lely AJ & Kopchick JJ. Growth hormone receptor antagonists. Neuroendocrinology 2006 83 264-268.
5. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L & Kleinberg DL. Octreotide as primary therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3034-3040.
6. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Cali A, de Divitiis E & Lombardi G. Effect of octreotide pretreatment on surgical outcome in acromegaly. Journal of Clinical Endocrinology and Metabolism 1997 82 3308-3314.
7. Plockinger U & Quabbe HJ. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochirurgica 2005 147 485-493 (discussion 493).
8. Wass J. Debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues. European Journal of Endocrinology 2005 152 693-694.
9. Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, Bowlers S, Trainer PJ & Wass JA. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clinical Endocrinology 2008 68 970-975.
10. Reincke M, Petersenn S, Buchfelder M, Gerbert B, Skrobek-Engel G, Franz H, Lohmann R & Quabbe HJ. The German Acromegaly Registry: description of the database and initial results. Experimental and Clinical Endocrinology and Diabetes 2006 114 498-505.
11. Bates PR, Carson MN, Trainer PJ & Wass JA. Wide variation in surgical outcomes for acromegaly in the UK. Clinical Endocrinology 2008 68 136-142.
12. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529.
13. Holdaway IM & Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999 2 29-41.
14. Ludecke DK & Abe T. Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations. Neuroendocrinology 2006 83 230-239.
15. Swearingen B, Barker FG II, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM & Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3419-3426.
16. Sheppard MC. GH and mortality in acromegaly. Journal of Endocrinological Investigation 2005 28 75-77.
17. Davis DH, Laws ER Jr, Ilstrup DM, Speed JK, Caruso M, Shaw EG, Abboud CF, Scheithauer BW, Root LM & Schleck C. Results of surgical treatment for growth hormone-secreting pituitary adenomas. Journal of Neurosurgery 1993 79 70-75.
18. Kreutzer J, Vance ML, Lopes MB & Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. Journal of Clinical Endocrinology and Metabolism 2001 86 4072-4077.
19. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB & Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism 1998 83 3411-3418.
20. De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS & Scanlon MF. Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. Journal of Clinical Endocrinology and Metabolism 2003 88 3567-3572.
21. Gittoes NJ, Sheppard MC, Johnson AP & Stewart PM. Outcome of surgery for acromegaly - the experience of a dedicated pituitary surgeon. Quarterly Journal of Medicine 1999 92 741-745.
22. Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen JA, Uitterlinden P, Hofland LJ, Lamberts SW, van der Lely AJ & de Herder WW. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. Journal of Clinical Endocrinology and Metabolism 2005 90 6480-6489.
23. Ronchi CL, Varca V, Giavoli C, Epaminonda P, Beck-Peccoz P, Spada A & Arosio M. Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. Journal of Clinical Endocrinology and Metabolism 2005 90 1377-1382.
24. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L & Pagani G. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. Journal of Clinical Endocrinology and Metabolism 2006 91 1397-1403.
25. Mercado M, Borges F, Bouterfa. H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M & Wardlaw J. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clinical Endocrinology 2007 66 859-868.
26. Grottoli S, Celleno R, Gasco V, Pivonello R, Caramella D, Barreca A, Ragazzoni F, Pigliaru F, Alberti D, Ferrara R & Angeletti G. Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study. Journal of Endocrinological Investigation 2005 28 978-983.
27. Jallad RS, Musolino NR, Salgado LR & Bronstein MD. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clinical Endocrinology 2005 63 168-175.
28. Melmed S, Vance ML, Barkan AL, Bengtsson BA, Kleinberg D, Klibanski A & Trainer PJ. Current status and future opportunities for controlling acromegaly. Pituitary 2002 5 185-196.
29. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA & Wardlaw JM. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Journal of Clinical Endocrinology and Metabolism 2002 87 4554-4563.
30. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF & Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. Journal of Clinical Endocrinology and Metabolism 2002 87 3537-3542.
31. Freda PU. How effective are current therapies for acromegaly? Growth Hormone and IGF Research 2003 13 (Suppl A) S144-S151.
32. Plockinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S & Schulz S. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. Journal of Clinical Endocrinology and Metabolism 2008 93 1203-1210.
33. Kristof RA, Stoffel-Wagner B, Klingmuller D & Schramm J. Does octreotide treatment improve the surgical results of macroadenomas in acromegaly? A randomized study Acta Neurochirurgica 1999 141 399-405.
34. Seidman PA, Kofke WA, Policare R & Young M. Anaesthetic complications of acromegaly. British Journal of Anaesthesia 2000 84 179-182.
35. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G & Cozzi R. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 2006 91 85-92.
36. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P & Beckers A. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. European Journal of Endocrinology 2005 152 61-66.
37. Jallad RS, Musolino NR, Kodaira S, Cescato VA & Bronstein MD. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clinical Endocrinology 2007 67 310-315.
38. Strasburger CJ & Bidlingmaier M. How robust are laboratory measures of growth hormone status? Hormone Research 2005 64 (Suppl 2) 1-5.
39. Parkinson C, Burman P, Messig M & Trainer PJ. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. Journal of Clinical Endocrinology and Metabolism 2007 92 190-195.
40. Bates AS, Evans AJ, Jones P & Clayton RN. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clinical Endocrinology 1995 42 417-423.
41. Dobrashian RD, O'Halloran DJ, Hunt A, Beardwell CG & Shalet SM. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly. Clinical Endocrinology 1993 38 589-593.
42. Parkinson C, Renehan AG, Ryder WD, O'Dwyer ST, Shalet SM & Trainer PJ. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clinical Endocrinology 2002 57 59-64.
43. Espinosa-de-Los-Monteros AL, Sosa E, Cheng S, Ochoa R, Sandoval C, Guinto G, Mendoza V, Hernandez I, Molina M & Mercado M. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clinical Endocrinology 2006 64 245-249.
44. Kalavalapalli S, Reid H, Kane J, Buckler H, Trainer P & Heald AH. Silent growth hormone secreting pituitary adenomas: IGF-1 is not sufficient to exclude growth hormone excess. Annals of Clinical Biochemistry 2007 44 89-93.